extracellular vesicle

Overview

Extracellular vesicles (EVs) are membrane-enclosed particles released by cells into the extracellular space. They include subtypes such as exosomes and microvesicles, and they function as carriers of proteins, lipids, Metabolites, and nucleic acids between cells. In biomedical research, EVs are widely studied as mediators of intercellular communication, immune regulation, tissue remodeling, and organ crosstalk. Because they circulate in body fluids and reflect the state of their cells of origin, they are also of interest as minimally invasive biomarkers.

Recent work has expanded EV research into both mechanistic biology and translational technology. EVs have been investigated as natural delivery vehicles for curcumin, cannabidiol, siRNA, miRNA inhibitors, and proteins such as hypoxia inducible factor 1 subunit alpha, as well as engineered platforms for cancer immunotherapy, fibrosis, asthma, stroke, neurodegeneration, and regenerative medicine. Their biological roles are closely linked to pathways involving PI3K/AKT, PTEN, mTOR, NLRP3 inflammasome signaling, ferroptosis, macrophage polarization, and dendritic cell modulation, making EVs a central technology in cell-free therapy and liquid biopsy development.

Recent Publications Summary

Recent studies have examined extracellular vesicles (EVs) as both therapeutic agents and disease biomarkers across regenerative medicine, inflammatory disease, and cancer diagnostics. In wound repair, adipose-derived stem cell EVs produced in a mechanically tunable GelMA/HAMA/PEGDA hybrid hydrogel showed regenerative-associated molecular signatures, including ECM-integrin interactions, focal adhesion-related pathways, PI3K-AKT signaling, and a keratin-enriched proteomic profile; these 3D-culture-derived EVs also enhanced HaCaT migration and increased p-AKT/AKT more strongly than dish-cultured EVs 42383565Jul. In ischemic stroke, plant-derived EVs from Ligusticum sinense chuanxiong were reported to cross the blood-brain barrier, accumulate in ischemic brain tissue, reprogram metabolism, and activate VEGF signaling through VEGFA, VEGFR2, and MAPK1-associated changes, supporting neurovascular repair 41610696Jan. Other therapeutic studies described Paeonia lactiflora-derived EVs that alleviated diabetic peripheral neuropathy by reducing Schwann cell apoptosis, suppressing CCL21/CCR7 signaling, and limiting CCR7+CD8+ T-cell infiltration 42241812Jun, as well as bone marrow mesenchymal stem cell EV treatment that was reported safe in an expanded-access trial for COVID-19 respiratory failure 42113080May.

Several publications focused on EV engineering or delivery platforms to improve tissue regeneration. platelet-rich plasma priming altered the miRNA cargo of bone marrow mesenchymal stem cell-derived exosomes and was associated with reduced neuronal apoptosis and autophagy and improved nerve regeneration after spinal cord injury via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis 42165939May. Human periodontal ligament cell exosomes loaded into a biodegradable piezoelectric fibrous membrane were designed for sustained release and vascularized periodontal bone regeneration 42012481Apr. Ultrasound-guided human umbilical cord mesenchymal stem cell transplantation was also reported to improve neuropathic pain and nerve repair in chronic constriction injury rats, with associated microglia/macrophage polarization changes and NLRP3 inflammasome modulation 41934900Apr. In a wound-healing context, bio-inspired hybrid hydrogels were used as both a 3D culture system and EV delivery scaffold to improve EV production and therapeutic potency 42383565Jul.

EVs were also investigated as biomarkers and analytical targets. In cirrhosis, circulating EVs were proposed to reflect thrombo-inflammatory, endothelial, and tissue-remodelling changes and to mirror disease severity and outcomes 42249626Jun. In metabolic liver disease, profiling of EVs from patient serum, primary hepatocytes, and liver organoids identified cell injury-specific protein signatures in metabolic dysfunction-associated steatohepatitis, including elevated SLC27A5, HP, and CXCL7 42236744Jun. In Parkinson's disease, serum exosome surface-enhanced Raman spectroscopy combined with support vector machine classification differentiated patients from controls with reported diagnostic performance 41689984Feb. A separate study used a biological optical nanocavity-coupled electrochemiluminescence sensor to detect EV glycosylation patterns in gastric cancer diagnosis, highlighting region-specific membrane curvature and glycoprotein distribution on EVs 41988862Apr. Molecular imprinting was further used to selectively capture EpCAM-positive tumor-derived EVs for proteomic biomarker discovery, supporting their use in liquid biopsy applications 42117374May.

Mechanistic studies also addressed EV biogenesis and immune signaling. In neutrophil-like HL-60 cells, P2X7 receptor signaling and BzATP stimulation increased exosome release through PI3K/AKT-dependent MRP1/ABCC1-mediated glutathione efflux and nSMase activity, linking redox regulation to EV formation 41856059Mar. A narrative review discussed dendritic cell EVs as a nanoparticle platform for cancer immunotherapy and antigen transfer to T-lymphocytes 42010708Apr. Together, these publications portray EVs as versatile biological entities with roles in intercellular communication, disease biomarker discovery, and cell-free therapy, with growing emphasis on cargo engineering, selective capture, and disease-specific functional profiling 42383565Jul42249626Jun42117374May41856059Mar.

What Changes, What Holds

1. EVs now look more context-sensitive therapeutic materials than generic repair signals
NEW DIRECTION Adipose-derived stem cell EVs produced in a mechanically tunable 3D hydrogel were reported to carry a more regeneration-linked cargo profile and stronger pro-migratory signaling than dish-cultured EVs, suggesting that the production environment can materially alter EV function 42383565Jul. That does not displace the baseline view of EVs as mediators of tissue remodeling, but it adds an important qualifier: therapeutic potency may depend on how the vesicles are generated, not just on the source cell.

2. EV-based repair is moving toward engineered delivery systems and cross-species sources
REINFORCES These studies extend the established regenerative and cell-free therapy uses of EVs by showing that cargo priming, scaffold loading, and plant-derived vesicles can all be harnessed for nerve, bone, and wound repair 42165939May42012481Apr. The baseline already frames EVs as delivery vehicles and regenerative tools, so the main change is practical rather than conceptual: the work sharpens how EVs might be deployed, while leaving their core therapeutic role intact.

3. Circulating EVs are becoming more useful as disease-state readouts, but assay standardization remains unsettled
REINFORCES Profiling studies strengthen the baseline claim that EVs can serve as minimally invasive biomarkers by linking circulating vesicle features to cirrhosis severity, metabolic liver injury, Parkinson’s disease classification, and gastric cancer detection 42249626Jun41689984Feb. These findings do not alter what EVs are understood to be; they make the biomarker case more concrete. What remains unresolved is how robustly such signatures transfer across platforms, because the paragraph emphasizes different analytical approaches rather than a single validated clinical assay.

4. EV biogenesis is more tightly coupled to redox and purinergic signaling than the baseline account states
NEW DIRECTION P2X7-driven exosome release through PI3K/AKT-dependent glutathione efflux and nSMase activity adds a mechanistic layer to EV formation that the overview does not cover 41856059Mar. That leaves the established roles of EVs in communication and therapy standing, but it broadens the biology of how vesicle output is regulated. The dendritic-cell review is consistent with the baseline’s immunotherapy emphasis, so the main update is the new biogenesis mechanism, not the review itself.

Overview update candidates: mechanochemical control of EV potency in 3D culture; EVs as disease biomarkers across cirrhosis; metabolic liver disease; Parkinson’s disease; and gastric cancer; P2X7/PI3K-AKT-linked regulation of exosome release.